MRNA vs GMAB
Head-to-Head Stock Analysis & Investment Rating
Last Updated: Aug 12, 2026
MRNA
GMAB
Investment Advisor Scores
GMAB
AI Analyst Insights
Detailed Metrics Comparison
| Metric | MRNA | GMAB | Winner |
|---|---|---|---|
|
Valuation
Lower P/E and PEG ratios suggest a stock may be undervalued relative to earnings and growth. Value investors prefer lower multiples. |
|||
| Forward P/E | 23.0415 | 18.1488 | GMAB |
| PEG Ratio | 0 | 2.0447 | Tie |
|
Growth
Higher revenue and earnings growth rates indicate a company is expanding faster. Strong growth often justifies premium valuations. |
|||
| Revenue Growth | 2.1% | 24.9% | GMAB |
| Earnings Growth | -85.1% | -9.4% | GMAB |
|
Quality & Profitability
Higher Tradestie Score and profit margins reveal how efficiently a company operates. Strong profitability indicates competitive advantages. |
|||
| Tradestie Score | 54.5/100 | 46.4/100 | MRNA |
| Profit Margin | -141.4% | 19.1% | GMAB |
|
Risk Profile
Lower Beta and Implied Volatility values indicate reduced market risk. Conservative investors favor stocks with less price volatility. |
|||
| Beta | 1.00 | 1.00 | Tie |
|
Sentiment
AI Recommendation reflects overall analyst and proprietary sentiment. Stronger recommendations signal higher conviction. |
|||
| AI Recommendation | HOLD | HOLD | Tie |
Relative Price Performance (Last 90 Days)
Current Technical Phase
MRNA
MarkupPrice above SMA50, rising 50-day trend (6.8% over 20 days), RSI 53
GMAB
MarkupPrice above SMA50, rising 50-day trend (3.6% over 20 days), RSI 68
Fundamentals Snapshot
| Metric | MRNA | GMAB |
|---|---|---|
| Market Cap | — | — |
| Forward P/E | -12.3 | 16.6 |
| Trailing P/E | — | 24.7 |
| Revenue (TTM) | — | — |
| Revenue Growth | 0.0% | 0.2% |
| Gross Margin | -0.7% | 0.9% |
| Operating Margin | -5.6% | 0.4% |
| EPS | -8.07 | 1.25 |
| Dividend Yield | — | — |